Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabine M Hermans

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
BMC Medicine|March 24, 2016
The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort studySabine M Hermans, Alison D Grant, Violet Chihota, et al.
Tropical Medicine & International Health : TM & IH|November 8, 2012
Unrecognised tuberculosis at antiretroviral therapy initiation is associated with lower CD4+ T cell recoverySabine M Hermans, Frank van Leth, Agnes N Kiragga, et al.
Antiviral Therapy|February 21, 2013
Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weightingSabine M Hermans, Yukari C Manabe, Agnes N Kiragga, et al.
The Lancet Regional Health. Europe|July 19, 2024
Factors associated with acceleration of clinical development for infectious diseases: a cross-sectional analysis of 10-year EMA registration dataHanna K de Jong, Sabine M Hermans, Sophie M Schuitenmaker, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 8, 2012
Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in UgandaSabine M Hermans, Barbara Castelnuovo, Catherine Katabira, et al.
BMC Infectious Diseases|June 18, 2017
Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort studySabine M Hermans, Juliet A Babirye, Olive Mbabazi, et al.
BMC Medical Ethics|November 27, 2025
Research ethics and integrity challenges in accelerated clinical trials, an interview studyClàudia Pallisé Perelló, Giulia Inguaggiato, Loïs van Eck, et al.
Globalization and Health|May 13, 2026
Building a case for accelerated clinical development of drugs and vaccines - what are the driving forces?Loïs C van Eck, Clàudia Pallisé Perelló, Natalie Evans, et al.
Tropical Diseases, Travel Medicine and Vaccines|July 6, 2025
Malaria recrudescence after artemether-lumefantrine treatment in travellers- a hospital-based observational study and literature reviewJenny L Schnyder, Bache E Bache, Mika Hoogakker, et al.
BMJ Open|November 28, 2024
Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TBKogieleum Naidoo, Anushka Naidoo, Alash'le G Abimiku, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
BMC Medicine|March 24, 2016
The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort studySabine M Hermans, Alison D Grant, Violet Chihota, et al.
Tropical Medicine & International Health : TM & IH|November 8, 2012
Unrecognised tuberculosis at antiretroviral therapy initiation is associated with lower CD4+ T cell recoverySabine M Hermans, Frank van Leth, Agnes N Kiragga, et al.
Antiviral Therapy|February 21, 2013
Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weightingSabine M Hermans, Yukari C Manabe, Agnes N Kiragga, et al.
The Lancet Regional Health. Europe|July 19, 2024
Factors associated with acceleration of clinical development for infectious diseases: a cross-sectional analysis of 10-year EMA registration dataHanna K de Jong, Sabine M Hermans, Sophie M Schuitenmaker, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 8, 2012
Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in UgandaSabine M Hermans, Barbara Castelnuovo, Catherine Katabira, et al.
BMC Infectious Diseases|June 18, 2017
Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort studySabine M Hermans, Juliet A Babirye, Olive Mbabazi, et al.
BMC Medical Ethics|November 27, 2025
Research ethics and integrity challenges in accelerated clinical trials, an interview studyClàudia Pallisé Perelló, Giulia Inguaggiato, Loïs van Eck, et al.
Globalization and Health|May 13, 2026
Building a case for accelerated clinical development of drugs and vaccines - what are the driving forces?Loïs C van Eck, Clàudia Pallisé Perelló, Natalie Evans, et al.
Tropical Diseases, Travel Medicine and Vaccines|July 6, 2025
Malaria recrudescence after artemether-lumefantrine treatment in travellers- a hospital-based observational study and literature reviewJenny L Schnyder, Bache E Bache, Mika Hoogakker, et al.
BMJ Open|November 28, 2024
Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TBKogieleum Naidoo, Anushka Naidoo, Alash'le G Abimiku, et al.
Pageof 3